CN107683137A - 用于使用stat3途径抑制剂和激酶抑制剂治疗癌症的方法 - Google Patents

用于使用stat3途径抑制剂和激酶抑制剂治疗癌症的方法 Download PDF

Info

Publication number
CN107683137A
CN107683137A CN201680032224.8A CN201680032224A CN107683137A CN 107683137 A CN107683137 A CN 107683137A CN 201680032224 A CN201680032224 A CN 201680032224A CN 107683137 A CN107683137 A CN 107683137A
Authority
CN
China
Prior art keywords
compound
cancer
formula
foregoing
pharmaceutically acceptable
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN201680032224.8A
Other languages
English (en)
Chinese (zh)
Inventor
C·J·李
Y·李
H·罗戈夫
高媛
J·黄
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Boston Bio Pharmaceutical Co Ltd
Original Assignee
Boston Bio Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boston Bio Pharmaceutical Co Ltd filed Critical Boston Bio Pharmaceutical Co Ltd
Publication of CN107683137A publication Critical patent/CN107683137A/zh
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Furan Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
CN201680032224.8A 2015-04-27 2016-04-26 用于使用stat3途径抑制剂和激酶抑制剂治疗癌症的方法 Pending CN107683137A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201562153385P 2015-04-27 2015-04-27
US62/153,385 2015-04-27
PCT/US2016/029328 WO2016176190A1 (en) 2015-04-27 2016-04-26 Methods for treating cancer with a stat3 pathway inhibitor and kinase inhibitor

Publications (1)

Publication Number Publication Date
CN107683137A true CN107683137A (zh) 2018-02-09

Family

ID=56081544

Family Applications (1)

Application Number Title Priority Date Filing Date
CN201680032224.8A Pending CN107683137A (zh) 2015-04-27 2016-04-26 用于使用stat3途径抑制剂和激酶抑制剂治疗癌症的方法

Country Status (16)

Country Link
US (1) US20180250261A1 (enExample)
EP (1) EP3288552A1 (enExample)
JP (2) JP2018514557A (enExample)
KR (1) KR20170141716A (enExample)
CN (1) CN107683137A (enExample)
AU (1) AU2016255034A1 (enExample)
BR (1) BR112017022958A2 (enExample)
CA (1) CA2983468A1 (enExample)
EA (1) EA201792320A1 (enExample)
HK (1) HK1252172A1 (enExample)
IL (1) IL255023A0 (enExample)
MX (1) MX2017013816A (enExample)
PH (1) PH12017501882A1 (enExample)
SG (1) SG11201708506QA (enExample)
TW (1) TW201713329A (enExample)
WO (1) WO2016176190A1 (enExample)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022178957A1 (zh) * 2021-02-25 2022-09-01 毕庶壮 Napabucasin的制药用途

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2736564A1 (en) 2007-09-10 2009-03-19 Boston Biomedical, Inc. Novel compositions and methods for cancer treatment
SG11201508358RA (en) 2013-04-09 2015-11-27 Boston Biomedical Inc 2-acetylnaphtho[2,3-b]furan -4,9-dione for use on treating cancer
CA3029596A1 (en) * 2016-06-28 2018-01-04 Boston Biomedical, Inc. Methods for treating cancer
WO2018102427A1 (en) 2016-11-29 2018-06-07 Boston Biomedical, Inc. Naphthofuran derivatives, preparation, and methods of use thereof
JP2020520923A (ja) 2017-05-17 2020-07-16 ボストン バイオメディカル， インコーポレイテッド がんを処置するための方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101848908A (zh) * 2007-09-06 2010-09-29 波士顿生物医药公司 激酶抑制剂的组合物及其在治疗癌症和其它与激酶相关的疾病中的用途
CN101854802A (zh) * 2007-09-10 2010-10-06 波士顿生物医药公司 用于癌症治疗的新组合物和方法

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201508358RA (en) * 2013-04-09 2015-11-27 Boston Biomedical Inc 2-acetylnaphtho[2,3-b]furan -4,9-dione for use on treating cancer

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101848908A (zh) * 2007-09-06 2010-09-29 波士顿生物医药公司 激酶抑制剂的组合物及其在治疗癌症和其它与激酶相关的疾病中的用途
CN101854802A (zh) * 2007-09-10 2010-10-06 波士顿生物医药公司 用于癌症治疗的新组合物和方法

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022178957A1 (zh) * 2021-02-25 2022-09-01 毕庶壮 Napabucasin的制药用途

Also Published As

Publication number Publication date
SG11201708506QA (en) 2017-11-29
PH12017501882A1 (en) 2018-03-05
EP3288552A1 (en) 2018-03-07
CA2983468A1 (en) 2016-11-03
JP2021121629A (ja) 2021-08-26
EA201792320A1 (ru) 2018-02-28
HK1252172A1 (zh) 2019-05-17
US20180250261A1 (en) 2018-09-06
WO2016176190A1 (en) 2016-11-03
BR112017022958A2 (pt) 2018-07-17
KR20170141716A (ko) 2017-12-26
IL255023A0 (en) 2017-12-31
JP2018514557A (ja) 2018-06-07
TW201713329A (zh) 2017-04-16
MX2017013816A (es) 2018-11-12
AU2016255034A1 (en) 2017-11-02

Similar Documents

Publication Publication Date Title
CN107683137A (zh) 用于使用stat3途径抑制剂和激酶抑制剂治疗癌症的方法
US20180085341A1 (en) Methods for treating cancer
JP2020169222A (ja) 癌を治療するための方法
US10646464B2 (en) Methods for treating cancer
WO2018005444A2 (en) Methods for treating cancer
US20180098959A1 (en) Methods for treating cancer
US20250235425A1 (en) New Combination Solution for Treating Chemotherapy Refractory Cancer
HK40047114A (en) New combination solution for treating chemotherapy refractory cancer

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
WD01 Invention patent application deemed withdrawn after publication
WD01 Invention patent application deemed withdrawn after publication

Application publication date: 20180209